Ganciclovir
- Generic Name
- Ganciclovir
- Brand Names
- Cytovene, Zirgan
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13N5O4
- CAS Number
- 82410-32-0
- Unique Ingredient Identifier
- P9G3CKZ4P5
- Background
An acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections.
- Indication
For induction and maintenance in the treatment of cytomegalovirus (CMV) retinitis in immunocompromised patients, including patients with acquired immunodeficiency syndrome (AIDS). Also used in the treatment of severe cytomegalovirus (CMV) disease, including CMV pneumonia, CMV gastrointestinal disease, and disseminated CMV infections, in immunocompromised pat...
- Associated Conditions
- CMV colitis, Cytomegalovirus (CMV) Infections, Cytomegalovirus Retinitis, Cytomegalovirus gastroesophagitis, Varicella-zoster Progressive outer retinal necrosis, Acute Herpetic keratitis, Cytomegalovirus neurological disease, Varicella-zoster virus acute retinal necrosis
- Associated Therapies
- -
Preliminary Results for the Double-dose Adenovirus-mediated Adjuvant Therapy Improving Outcome of Liver Transplantation in Patients With Advanced Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2014-07-29
- Last Posted Date
- 2014-07-29
- Lead Sponsor
- Huazhong University of Science and Technology
- Target Recruit Count
- 81
- Registration Number
- NCT02202564
PTH - Preemptive Treatment for Herpesviridae
- First Posted Date
- 2014-06-02
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Assistance Publique Hopitaux De Marseille
- Target Recruit Count
- 317
- Registration Number
- NCT02152358
- Locations
- 🇫🇷
Assistance Publique - Hôpitaux de Marseille, Marseille, France
Topical Administration of 0.15% Ganciclovir Gel for CMV Anterior Uveitis / Endotheliitis
- Conditions
- Interventions
- First Posted Date
- 2012-07-23
- Last Posted Date
- 2015-11-18
- Lead Sponsor
- Singapore National Eye Centre
- Target Recruit Count
- 29
- Registration Number
- NCT01647529
- Locations
- 🇸🇬
Singapore National Eye Centre, Singapore, Singapore
Evaluate the Use of Ganciclovir Gel 0.3% for the Treatment of Conjunctivitis Caused by Adenovirus
- Conditions
- Interventions
- First Posted Date
- 2012-05-17
- Last Posted Date
- 2012-05-17
- Lead Sponsor
- Adapt Produtos Oftalmológicos Ltda.
- Target Recruit Count
- 22
- Registration Number
- NCT01600365
A Placebo Controlled Comparison of Topical Zirgan Versus Genteal Gel for the Treatment of Adenovirus Conjunctivitis
- Conditions
- Interventions
- First Posted Date
- 2012-02-15
- Last Posted Date
- 2018-02-28
- Lead Sponsor
- Lifelong Vision Foundation
- Target Recruit Count
- 20
- Registration Number
- NCT01533480
- Locations
- 🇺🇸
Lifelong Vision Foundation, Chesterfield, Missouri, United States
Ganciclovir 0,15% Ophthalmic Gel in the Treatment of Adenovirus Keratoconjuntivitis
- Conditions
- Interventions
- First Posted Date
- 2011-05-06
- Last Posted Date
- 2011-05-06
- Lead Sponsor
- Federal University of São Paulo
- Target Recruit Count
- 33
- Registration Number
- NCT01349452
- Locations
- 🇧🇷
Federal University of Sao Paulo, São Paulo, Brazil
Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant
- Conditions
- Anaplastic Large Cell LymphomaContiguous Stage II Adult Immunoblastic Large Cell LymphomaContiguous Stage II Grade 1 Follicular LymphomaContiguous Stage II Mantle Cell LymphomaNoncontiguous Stage II Grade 3 Follicular LymphomaNoncontiguous Stage II Small Lymphocytic LymphomaRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Grade III Lymphomatoid GranulomatosisSplenic Marginal Zone Lymphoma
- Interventions
- Procedure: infection prophylaxis and managementOther: laboratory biomarker analysisOther: flow cytometryGenetic: DNA analysisGenetic: RNA analysisProcedure: management of therapy complicationsDrug: ganciclovirDrug: valganciclovirDrug: foscarnet sodiumProcedure: antiviral therapyGenetic: polymerase chain reactionGenetic: protein expression analysis
- First Posted Date
- 2010-09-13
- Last Posted Date
- 2019-04-25
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 153
- Registration Number
- NCT01199562
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Study Comparing Valganciclovir Versus Ganciclovir in Patients Following Allogeneic Stem Cell Transplantation
- Conditions
- Interventions
- First Posted Date
- 2010-08-19
- Last Posted Date
- 2012-12-10
- Lead Sponsor
- Pierrel Research Europe GmbH
- Target Recruit Count
- 212
- Registration Number
- NCT01185223
- Locations
- 🇦🇹
Pierrel Site 50, Vienna, Austria
🇩🇪Pierrel Site 12, Berlin, Germany
🇩🇪Pierrel Site 13, Berlin, Germany
T-Lymphocyte Infusion or Standard Therapy in Treating Patients at Risk of Cytomegalovirus Infection After a Donor Stem Cell Transplant
- Conditions
- First Posted Date
- 2009-09-30
- Last Posted Date
- 2013-08-26
- Lead Sponsor
- University Hospital Birmingham
- Target Recruit Count
- 78
- Registration Number
- NCT00986557
- Locations
- 🇬🇧
Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust, Birmingham, England, United Kingdom
Study of Arginine Butyrate and Ganciclovir/Valganciclovir in EBV(+) Lymphoid Malignancies
- Conditions
- Interventions
- First Posted Date
- 2009-06-10
- Last Posted Date
- 2011-08-01
- Lead Sponsor
- HemaQuest Pharmaceuticals Inc.
- Target Recruit Count
- 1
- Registration Number
- NCT00917826
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.